DesignQ Developer, Author at AdvanCell

UroToday: Oliver Sartor MD interviews AdvanCell CMO Anna Karmann MD PhD on the current state and future of radiopharmaceuticals and the advantages of Lead-212

Source: UroToday Lead-212 Radiopharmaceuticals: Advancing Targeted Alpha Therapy in Oncology - Anna Karmann Oliver Sartor…

DesignQ Developer30 August 2024

Presentations/Publications

First-in-Human 212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

Source: AdvanCell First-in-Human 212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer There…

DesignQ Developer29 February 2024

News

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer January 4, 2024 - SYDNEY,…

DesignQ Developer4 January 2024

News

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of ²¹²Pb-ADVC001 in Metastatic Prostate Cancer

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic…

DesignQ Developer8 November 2023

News

AdvanCell Announces Flagship Facility

AdvanCell Announces the Launch of its Flagship Facility to Support Global Scaled Manufacture of Targeted…

DesignQ Developer3 November 2023

News

AdvanCell Delivers ²¹²Pb-ADVC001 to the Peter MacCallum Cancer Centre

AdvanCell delivers 212Pb-ADVC001, a development stage Targeted Alpha Therapy for Prostate Cancer to the Peter…

DesignQ Developer7 September 2023

News

AdvanCell a Successful Recipient of the CRC Project Selection Round

Source: Cooperative Research Centre Projects (CRC-P) GrantsCRC Projects selection round outcomes Cooperative Research Centres Projects…

DesignQ Developer30 June 2023

News

Advancell awarded a $9.8M in federal funding

Source: Australian Government Ministers Department of Health and Aging$73 million for new medical technology and…

DesignQ Developer27 June 2023

News

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

Source: POINT BiopharmaPOINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands POINT’s…

DesignQ Developer26 June 2023

News

Heavy Metal Therapy: Realising the potential of ²¹²Pb targeted alpha therapies

Source: WebsEdge/MedicineRadionuclide therapies are sparking a revolution in nuclear medicine and are changing the way…

DesignQ Developer25 June 2023

News

DesignQ Developer

UroToday: Oliver Sartor MD interviews AdvanCell CMO Anna Karmann MD PhD on the current state and future of radiopharmaceuticals and the advantages of Lead-212

First-in-Human 212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of ²¹²Pb-ADVC001 in Metastatic Prostate Cancer

AdvanCell Announces Flagship Facility

AdvanCell Delivers ²¹²Pb-ADVC001 to the Peter MacCallum Cancer Centre

AdvanCell a Successful Recipient of the CRC Project Selection Round

Advancell awarded a $9.8M in federal funding

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

Heavy Metal Therapy: Realising the potential of ²¹²Pb targeted alpha therapies

Latest News

Quick Links

Locations

Contact Us

Locations